Superficial spreading melanoma (SSM) and nodular melanoma (NM) are believed to represent sequential phases of linear progression from radial to vertical growth. Several lines of clinical, pathological and epidemiologic evidence suggest, however, that SSM and NM might be the result of independent pathways of tumor development. We utilized an integrative genomic approach that combines single nucleotide polymorphism array (SNP 6.0, Affymetrix) with gene expression array (U133A 2.0, Affymetrix) to examine molecular differences between SSM and NM. Pathway analysis of the most differentially expressed genes between SSM and NM (N=114) revealed significant differences related to metabolic processes. We identified 8 genes (DIS3, FGFR1OP, G3BP2, GALNT7, MTAP, SEC23IP, USO1, ZNF668) in which NM/SSM-specific copy number alterations correlated with differential gene expression (P<0.05, Spearman's rank). SSM-specific genomic deletions in G3BP2, MTAP, and SEC23IP were independently verified in two external data sets.
INTRODUCTION
Superficial spreading melanoma (SSM) and nodular melanoma (NM), the two most common histopathologic subtypes (70% and 20% respectively), are characterized by markedly different clinical presentations and natural histories. NM has a higher rate of recurrence (1, 2) and has not demonstrated the same degree of downward stage migration at initial presentation relative to SSM (3). These differences are generally attributed solely to the advanced thickness of NM, with no prognostic relevance assigned to histopathological subtype in melanomas of equivalent thickness. Previous studies by several groups including ours, however, suggest that underlying molecular differences between the two subtypes may also contribute to the disparate outcomes (4) (5) (6) .
It is generally accepted that SSM and NM develop along a linear pathway of progression that begins with transformation of epidermal melanocytes and differs between subtypes primarily with respect to the speed with which the transformed melanocytes invade the dermis (7, 8) . Until the identification of distinct molecular alterations characterizing acral melanoma such as c-KIT mutation and amplification (9) (10) (11) , all melanoma subtypes were typically viewed as a relatively homogenous biologic entity (8) . Advances in genomic technology in the setting of a broader recognition of the biologic heterogeneity of cancer have changed this long-held view, at least for acral melanoma. As such, clinical trials evaluating the efficacy of c-KIT inhibitor imatinib for patients with metastatic melanoma from an acral primary are ongoing (12) . Currently, there is no definitive evidence to demonstrate that SSM and NM are molecularly different enough to warrant a unique molecular classification such as the one that has now been assigned to acral melanoma.
It is difficult to reconcile observed differences between SSM and NM, such as the minimal degree of epidermal involvement and the lack of a detectable radial growth phase in NM, with the current linear progression model. To our knowledge, there are no studies that have evaluated the genomic and gene expression alterations that characterize SSM and NM. Using an integrative genomic approach, we examined the hypothesis that SSM and NM follow separate pathways of development from the transformed melanocyte to the invasive primary melanoma that are characterized by subtype specific molecular alterations. Integrative genomic analyses. Correlation of copy number data with gene expression was performed using the Partek Genomic Suite (Partek St Louis, MO). Copy number gains and losses were detected using a Hidden Markov Model algorithm in the Partek copy number workflow for unpaired samples. (see Suppl. Methods for detailed analysis).
External validation.
Unprocessed data for 13SSM and 5NM human tissues were downloaded from the 2007 publication by Jaeger et al (4) . Data were then normalized using RMA and log transformed for a two-sample unpaired t-test with a Bonferroni correction for multiple testing. GenePattern was used for clustering and gene set enrichment analysis. The complete list of 540 transcripts differentially expressed between radial growth phase (RGP) and VGP in the 2009 publication by Scatolini et al. (15) was also used as an external validation.
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
qRT-PCR was used to verify the results of gene expression microarray data. Data were exported using SDS 2.3 and analyzed using the methods of Pfaffl (16) assuming 100% efficiency of amplification with normalization to four housekeeping genes:
TMPRSS2, PDLIM4, DHX15, and SNF8. These genes were selected based on their uniform expression across the data set (coefficient of variance <10%). Fold change was evaluated relative to melanocyte controls. Primer sequences are summarized in Supplementary Table 1A. Genomic qPCR. Five genes were evaluated for validation using genomic PCR: DIS3, G3BP2, MTAP, SEC23IP, and USO1. Gene-specific primers are shown in Supplementary Table 1B and housekeeping genes, UBE2E1 and GNS, were used as previously described (17) Functional annotation shows that differentially expressed transcripts between SSM and NM are related to metabolic pathways. Gene ontology (GO) analysis of differentially expressed genes between SSM and NM revealed enrichment for GO biologic process (BP) terms related to primary, cellular, and nucleic acid metabolic processes (Suppl. Table 4 ). The most enriched term with regard to number of genes was "metabolic process"
(total gene count 65, 55.1%; P=0.04) which included genes such as methylthioadenosine phosphorylase (MTAP), aldehyde dehydrogenase 7A1 (ALDH7A1), angiogenin (ANG), and dihydrofolate reductase (DHFR) (Suppl. Table 4 ). The two most statistically significant GO BP terms were "nucleic acid metabolic process" (total gene count 38, 32.2%, P=0.003) and "cellular component organization/biogenesis" (total gene count 27, 22.9%; P=0.001).
To prioritize the 114 differentially expressed NM/SSM, we focused on the 25 genes with differential expression in both analyses (the ANOVA and t-test; Suppl. Table 5 were underexpressed in SSM relative to NM, and all genes are related to cellular metabolism, consistent with the results of the pathway analysis (Suppl. Table 4 ).
Integrative genomic workflow yields 8 genes in which SSM/NM specific copy number changes are correlated with NM/SSM differential expression. NM/SSM-specific copy number gains and losses that mapped to regions coding for genes found to be differentially expressed between NM and SSM in our initial analysis (N=114) were evaluated for statistical correlation between copy number and mRNA expression level.
The integrative analysis revealed a list of 8 genes (DIS3, FGFR1OP, G3BP2, GALNT7, MTAP, SEC23IP, USO1, ZNF668) that met the following criteria: 1) NM/SSM-specific copy number gain or loss; 2) differential gene expression between NM and SSM; and 3) copy number significantly correlated with gene expression ( fold change between NM and SSM in opposite directions (MTAP lower in SSM, FGFR1OP higher in SSM), suggesting that these genes may hold increased biologic relevance. in SSM relative to NM) in the external data set by Jaeger (DIS3, Figure 3 and not shown). Only 3 of these genes (MTAP, SEC23IP, and G3BP2) were included in the Scatolini data set, but all were validated as having the same trend of expression between subtypes, with G3BP2 also showing statistically significant lower expression in SSM relative to NM in the external data set (15) . Validation of array results using western blot. ALDH7A1 and EPB41L3 were also prioritized for protein validation studies because, second only to MTAP, they had the highest (ALDH7A1) and most significant (EPB41L3) fold changes noted in the gene expression array (Suppl. Table 5 ). Expression of ALDH7A1, EPB41L3, and MTAP was assessed by western blot in the same primary melanoma cell lines used in the array as well as an additional SSM cell line (WM 1575) and 2 additional RGP-like cell lines (WM98.1 and WM 853.2). Consistent with the array results, ALDH7A1, a gene involved in the detoxification of aldehydes generated by lipid peroxidation, showed complete loss of expression in 2 of the 3 SSM cell lines relative to NM and melanocyte controls ( Figure 5A ). Also consistent with the array results, EPB41L3 showed complete loss of expression in all SSM cell lines relative to melanocytes. EPB41L3 showed higher expression in NM cell lines relative to SSM but lower expression in NM relative to normal which also verified the array results ( Figure 5A ).
MTAP expression was completely lost in the 2 SSM cell lines from the array (WM35 and WM 1552c) which was consistent with the genomic loss, and showed low expression in the additional SSM cell line (WM1575) relative to both NM and normal melanocytes.
Regulation of ALDH7A1 expression in SSM.
We first performed mutational analysis of ALDH7A1 (exons 2, 12, 14; introns 5, 16) in 7 vertical growth phase (VGP) and 4 radial growth phase (RGP) cell lines that revealed no evidence of mutation (Suppl. SSM is due to the epigenetic mechanisms. We found a significant (P<0.01) increase in ALDH7A1 mRNA levels in SSM WM1552c cells after treatment with 1uM azacytidine (Aza) and 200ng/ml Trichostatin A (TSA) ( Figure 5B). These data suggest that a combination of hypermethylation and deacetylation may be responsible for the lower expression of ALDH7A1 in SSM.
Validation of array results using immunohistochemistry (IHC). Expression of ALDH7A1, EPB41L3, and
MTAP was further evaluated using TMAs of 20 NM and 20 SSM human primary melanoma tissues. Baseline demographic and clinicopathologic data for these cases are presented in Table 2 . ALDH7A1 expression was significantly higher in NM cores relative to SSM. The mean intensity score (on a scale from 0-2) of NM cores Gene ontology (GO) analysis of differentially expressed genes between SSM and NM showed enrichment for genes related to metabolic processes. Aldehyde dehydrogenase 7A1 (ALDH7A1) demonstrated higher expression in human NM tissues relative to SSM that remained significant in a multivariate model controlling for thickness and ulceration. Recent studies have demonstrated that expression of aldehyde dehydrogenases can identify the presence of cancer stem cell populations in hepatocellular carcinoma (HCC) and breast cancer (18, 19) . Overexpression of ALDH7A1 in NM versus SSM may reflect differences in the percentage of tumor initiating cells that could explain NM's rapid vertical growth. Not only was expression of ALDH7A1 higher in NM relative to SSM and normal skin but SSM expression was lower in SSM relative to normal skin. Our data suggest that, in the absence of genomic losses and premature STOP codons, the lower expression of ALDH7A1 in SSM may be due to an epigenetic mechanism. ALDH7A1 is highly conserved throughout evolution and is homologous to ALDH7B1 in plants where overexpression of the enzyme is believed to indicate a global upregulation of the organism's response to environmental stress (20) . Similarly, ALDH7 and other ALDH family members are highly expressed in the lens of the murine eye where they have a protective effect against ultraviolet (UV)-induced DNA damage (21). Thus, it is possible that the loss of ALDH7A1 observed in SSM makes the subtype more susceptible to and/or more likely to be the result of carcinogenic exposures such as UV light.
The utilization of an integrative genomic approach makes it more likely that the alterations identified are biologically relevant. Genes previously identified as differentially expressed between NM and SSM using microarrays have not been further studied at the functional level, thus the underlying mechanisms that contribute to differential gene expression are not understood. Of note, one previous gene expression study of RGP and VGP melanoma revealed the unexpected finding that, within the same patient, the expression profile of the metastatic melanoma was consistent with a RGP-like signature, whereas the nodular primary exhibited a separate, VGP-like expression profile (22) . This observation is consistent with our principal component analysis of melanoma cell lines showing that SSM primary cell lines cluster with metastatic lesions, whereas all of the primary NMs fall outside of this cluster. Based on the relatively aggressive clinical behavior of NM relative to SSM, it might be expected that NM would cluster with the metastatic lesions. While we recognize the CAN-10-2958 exploratory nature of the PCA, the findings from these two independent studies showing that gene expression profiles of SSM and metastatic lesions are more closely related than the profiles of nodular primaries supports the hypothesis that NM and SSM represent different biological processes.
An array-based integrative genomic workflow and subsequent verification studies identified SSMspecific deletions in genes that were significantly correlated with gene expression. USO1 and G3BP2 are adjacent genes on chromosome 4q21.1. USO1 has been primarily studied in yeast where it is involved in transport between the endoplasmic reticulum and the Golgi apparatus (23) . It is notable that both of our in silico analyses of external data sets confirmed our results showing lower expression of G3BP2 in SSM relative to NM (4, 15) . G3BP2 is a relatively recently characterized GTP-ase activating protein that is overexpressed in breast cancer (24) and that plays a role in the regulation of NFkB signaling (25) , a pathway known to be altered in melanoma.
DIS3 has been shown to function in the regulation of proper chromosomal segregation during mitosis, and DIS3 mutant yeast cells have increased sensitivity to microtubule destabilizing agents such as thiabendazole (26) . In this regard, molecular compound library screening studies by our group showed that mebendazole, a microtubule-destabilizing drug, demonstrated subtype specific efficacy such that SSM cell lines were sensitive, but NM cells were resistant (5) . Further supporting the potential biologic relevance of the genes identified by our integrative genomic analysis, two independent gene expression profiling studies of colorectal cell lines and human tissues have identified overexpression of DIS3 as high as 38-fold in primary and metastatic tumors relative to normal colonic mucosa (27, 28) . Thus, the overexpression and increased DNA copy number indentified in the region of DIS3 in our NM cell lines may play a role in its rapid vertical growth and aggressive behavior. The same gene, however, also shows genomic deletion and reduced expression in SSM cell lines.
Thus, SSM-specific genomic deletions such as the ones noted in the region of DIS3 may play a mechanistic role in the observed increased sensitivity of SSM cells to microtubule destabilizing agents.
A previous gene expression profiling study identified SEC23IP as an important mediator of bone formation and metabolism (29) . Interestingly, 3 of the top candidate genes from that study (IFIT3, SEC23IP, and PPP2R2D) were also found to be among the most differentially expressed between NM and SSM in our study. While the link between these two investigations is not immediately apparent, many pathways known to play a role in carcinogenesis, such as interferon signaling and other cytokines, are also important in bone formation and metabolism (30) . SEC23IP has also recently been identified as a candidate gene for Waardenberg syndrome, a disorder characterized by craniofacial defects and pigment abnormalities, after it was shown that knockdown of sec23ip in the Xenopus embryo resulted in impaired migration of neural crest cells (31) .
Methylthioadenosine phosphorylase (MTAP), maps to 9p21.3 and is commonly co-deleted with tumor suppressor p16 (CDKN2A) (32) . MTAP plays a critical role in the salvage pathway of adenine and methionine and has previously been reported to be lost in several tumors including melanoma (33) . Our results demonstrate lower expression of MTAP in SSM relative to NM which was significantly correlated with SSM-specific genomic deletions in the region of 9p21. In conclusion, our data support a separate molecular classification of SSM and NM. Further functional studies of genes that are specifically deleted in SSM may better define their roles as potential drivers of subtype specific tumorigenesis. 
